Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3259
Abstract: Abstract Purpose Anti‐CD19 chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due… read more here.
Keywords: cd19; anti cd19; antigen; cd20 ... See more keywords
Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti‐CD19 chimeric antigen receptor T‐cell efficacy
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34532
Abstract: Autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy is an effective treatment for approximately 40% of relapsed/refractory large B cell lymphomas (LBCL), and early identification of patients at risk for relapse or progression after CAR… read more here.
Keywords: cell; antigen receptor; chimeric antigen; cd19 chimeric ... See more keywords
Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma
Sign Up to like & getrecommendations! Published in 2018 at "Current Hematologic Malignancy Reports"
DOI: 10.1007/s11899-018-0482-6
Abstract: Purpose of ReviewThis article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma.Recent FindingsThe clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis… read more here.
Keywords: cell; large cell; anti cd19; diffuse large ... See more keywords
Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro.
Sign Up to like & getrecommendations! Published in 2020 at "Immunology letters"
DOI: 10.1016/j.imlet.2020.04.005
Abstract: In spite of impressive results in the treatment of acute lymphoblastic B cell leukemia (B-ALL) with chimeric antigen receptor (CAR) T cells, the clinical outcome of some hematological cancers like follicular lymphoma (FL) and chronic… read more here.
Keywords: a2ar; anti cd19; pharmacological targeting; car cells ... See more keywords
Prophylactic tocilizumab before CD3/4-1bb anti-CD19 car-T cell infusion decreases incidence of severe crs without increased risk of neurotoxicity
Sign Up to like & getrecommendations! Published in 2020 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2020.03.483
Abstract: Background & Aim Anti-CD19 CAR-T cells have demonstrated activity against relapsed/refractory lymphomas. Cytokine release syndrome (CRS) and CAR-T related encephalopathy syndrome (CRES) are well-known complications of CAR-T cell therapy. Tocilizumab, a humanized monoclonal antibody targeting… read more here.
Keywords: car cell; crs; anti cd19; car ... See more keywords
EVALUATION OF ANTI-CD19 CAR-T CELL PERSISTENCE AND EFFICACY USING A DEVELOPED MULTIPARAMETRIC FLOW CYTOMETRY AND QPCR TRACKING PLATFORM FOR PRECLINICAL AND CLINICAL STUDIES
Sign Up to like & getrecommendations! Published in 2021 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2021.02.043
Abstract: Background Anti-CD19 chimeric antigen receptor (CAR)-expressing T cells have shown remarkable remission rates in acute B cell leukemias. It has been reported that anti-CD19 CAR-T cells sustain complete remission of leukemia even when their numbers… read more here.
Keywords: flow cytometry; anti cd19; cell; cd19 car ... See more keywords
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Sign Up to like & getrecommendations! Published in 2022 at "Nature medicine"
DOI: 10.1038/s41591-022-01702-9
Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented responses in patients with high-risk hematologic malignancies. However, up to 60% of patients still experience disease relapse and up to 80% of patients… read more here.
Keywords: therapy; microbiome; anti cd19; car cell ... See more keywords
Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies
Sign Up to like & getrecommendations! Published in 2022 at "Oncoimmunology"
DOI: 10.1080/2162402x.2022.2054106
Abstract: ABSTRACT Cancer immunotherapy strategies based on the endogenous secretion of T cell-redirecting bispecific antibodies by engineered T lymphocytes (STAb-T) are emerging as alternative or complementary approaches to those based on chimeric antigen receptors (CAR-T). The… read more here.
Keywords: stab cells; topology; cd19; anti cd19 ... See more keywords
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti‐CD19 CAR‐T cells
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18596
Abstract: Cytokine release syndrome (CRS) and consumptive coagulopathy can complicate the treatment with chimeric antigen receptor T (CAR‐T) cells. The modified version of the Endothelial Activation and Stress Index (mEASIX), a score derived from haematopoietic stem… read more here.
Keywords: release syndrome; anti cd19; car; car cells ... See more keywords
Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-0101
Abstract: Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cells represent a novel immunotherapy and are highly effective in treating relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL). How tumor microenvironment influences clinical response to CAR T therapy remains of… read more here.
Keywords: tumor microenvironment; anti cd19; cell; car ... See more keywords
Abstract 1537: Anti-CD19 ARTEMIS™ T cells prevent excessive inflammatory cytokine release, including IL-6, in a co-culture model of CRS
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-1537
Abstract: We designed the ARTEMISTM T-cell signaling platform to be a safer ACT therapy by relying on endogenous T-cell signaling factors. We show evidence that the ARTEMISTM receptor disentangles efficacy from CRS and holds the potential… read more here.
Keywords: cd19; crs; anti cd19; car cells ... See more keywords